Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Omega-3 fatty acid supplementation and total homocysteine levels in end-stage renal disease patients.

Beavers KM, Beavers DP, Bowden RG, Wilson RL, Gentile M.

Nephrology (Carlton). 2008 Jun;13(4):284-8. doi: 10.1111/j.1440-1797.2008.00934.x. Epub 2008 Mar 5.

PMID:
18331436
2.

Effect of over-the-counter fish-oil administration on plasma Lp(a) levels in an end-stage renal disease population.

Beavers KM, Beavers DP, Bowden RG, Wilson RL, Gentile M.

J Ren Nutr. 2009 Nov;19(6):443-9. doi: 10.1053/j.jrn.2009.06.005. Epub 2009 Sep 12.

PMID:
19748798
3.

The content of docosahexaenoic acid in serum phospholipid is inversely correlated with plasma homocysteine levels in patients with end-stage renal disease.

Rasmussen LE, Svensson M, Jørgensen KA, Schmidt EB, Christensen JH.

Nutr Res. 2010 Aug;30(8):535-40. doi: 10.1016/j.nutres.2010.07.004.

PMID:
20851307
4.
5.

Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease.

Bowden RG, Wilson RL, Deike E, Gentile M.

Nutr Clin Pract. 2009 Aug-Sep;24(4):508-12. doi: 10.1177/0884533609335376. Epub 2009 May 21.

PMID:
19461006
6.

Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study.

Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2554-8.

7.

Intravenous administration of vitamin B12 in the treatment of hyperhomocysteinemia associated with end-stage renal disease.

Vrentzos GE, Papadakis JA, Vardakis KE, Maliaraki N, Stilianou K, Arvanitis A, Sratigis S, Alivanis P, Margioris AN, Ganotakis ES.

J Nephrol. 2003 Jul-Aug;16(4):535-9.

PMID:
14696755
8.

Homocysteine lowering effect of different multivitamin preparations in patients with end-stage renal disease.

Dierkes J, Domröse U, Bosselmann KP, Neumann KH, Luley C.

J Ren Nutr. 2001 Apr;11(2):67-72.

PMID:
11295026
10.

Effects of omega-3 fatty acid supplementation on lipid levels in endstage renal disease patients.

Bowden RG, Jitomir J, Wilson RL, Gentile M.

J Ren Nutr. 2009 Jul;19(4):259-66. doi: 10.1053/j.jrn.2009.01.030.

PMID:
19539180
11.

Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.

Gonin JM, Nguyen H, Gonin R, Sarna A, Michels A, Masri-Imad F, Bommareddy G, Chassaing C, Wainer I, Loya A, Cary D, Barker LF, Assefi A, Greenspan R, Mahoney D, Wilcox CS.

J Nephrol. 2003 Jul-Aug;16(4):522-34.

PMID:
14696754
12.

Elevated homocysteine levels in patients with end-stage renal disease.

Nair AP, Nemirovsky D, Kim M, Geer EB, Farkouh ME, Winston J, Halperin JL, Robbins MJ.

Mt Sinai J Med. 2005 Nov;72(6):365-73.

PMID:
16358160
13.

Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease.

Elian KM, Hoffer LJ.

Metabolism. 2002 Jul;51(7):881-6.

PMID:
12077735
14.

Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients.

Azadibakhsh N, Hosseini RS, Atabak S, Nateghiyan N, Golestan B, Rad AH.

Saudi J Kidney Dis Transpl. 2009 Sep;20(5):779-88.

15.

Homocysteine and vascular access thrombosis in end-stage renal disease patients: a retrospective study.

Bowden RG, Wyatt FB, Wilson R.

J Nephrol. 2002 Nov-Dec;15(6):666-70.

PMID:
12495281
16.

Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial.

House AA, Eliasziw M, Urquhart BL, Freeman DJ, Spence JD.

Am J Kidney Dis. 2004 Oct;44(4):689-94.

PMID:
15384020
17.

The effect of long-term intravenous high dose B-complex vitamins with or without folic acid on serum homocysteine in hemodialysis patients.

Sombolos K, Fragia T, Natse T, Bartholomatos G, Karagianni A, Katsaris G, Christidou F, Bamichas G, Stangou M, Papagalanis N.

J Nephrol. 2002 Nov-Dec;15(6):671-5.

PMID:
12495282
18.

Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study.

Sunder-Plassmann G, Födinger M, Buchmayer H, Papagiannopoulos M, Wojcik J, Kletzmayr J, Enzenberger B, Janata O, Winkelmayer WC, Paul G, Auinger M, Barnas U, Hörl WH.

J Am Soc Nephrol. 2000 Jun;11(6):1106-16.

19.

Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial.

Urquhart BL, Freeman DJ, Cutler MJ, Mainra R, Spence JD, House AA.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1041-7. doi: 10.2215/CJN.04771107. Epub 2008 Mar 12.

20.

Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation.

Koyama K, Usami T, Takeuchi O, Morozumi K, Kimura G.

Nephrol Dial Transplant. 2002 May;17(5):916-22.

PMID:
11981084

Supplemental Content

Support Center